$1.16 Million in Sales Expected for AcelRx Pharmaceuticals Inc (ACRX) This Quarter

Equities analysts forecast that AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) will announce sales of $1.16 million for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for AcelRx Pharmaceuticals’ earnings. The lowest sales estimate is $450,000.00 and the highest is $2.20 million. AcelRx Pharmaceuticals posted sales of $340,000.00 in the same quarter last year, which would indicate a positive year-over-year growth rate of 241.2%. The business is expected to announce its next earnings report on Wednesday, May 8th.

According to Zacks, analysts expect that AcelRx Pharmaceuticals will report full year sales of $8.97 million for the current fiscal year, with estimates ranging from $6.51 million to $13.40 million. For the next year, analysts forecast that the business will post sales of $36.57 million, with estimates ranging from $31.72 million to $47.20 million. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that follow AcelRx Pharmaceuticals.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last issued its quarterly earnings data on Thursday, March 7th. The specialty pharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.20) by $0.02. The company had revenue of $0.61 million for the quarter, compared to the consensus estimate of $3.10 million.

ACRX has been the subject of a number of research analyst reports. Zacks Investment Research cut AcelRx Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, January 3rd. Cantor Fitzgerald set a $9.00 price target on AcelRx Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, January 29th. Credit Suisse Group initiated coverage on AcelRx Pharmaceuticals in a report on Friday, February 15th. They issued an “outperform” rating and a $7.00 price target for the company. LADENBURG THALM/SH SH set a $10.00 price target on AcelRx Pharmaceuticals and gave the company a “buy” rating in a report on Friday, March 8th. Finally, BidaskClub raised AcelRx Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, April 1st. Two investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $7.84.

In other AcelRx Pharmaceuticals news, Director Mark G. Edwards acquired 19,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 12th. The stock was acquired at an average cost of $2.99 per share, for a total transaction of $56,810.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders have bought a total of 26,721 shares of company stock valued at $78,506 over the last 90 days. Corporate insiders own 25.50% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of ACRX. BlackRock Inc. raised its stake in shares of AcelRx Pharmaceuticals by 196.6% during the 4th quarter. BlackRock Inc. now owns 2,331,736 shares of the specialty pharmaceutical company’s stock worth $5,386,000 after purchasing an additional 1,545,702 shares in the last quarter. Vanguard Group Inc grew its holdings in AcelRx Pharmaceuticals by 26.3% in the 3rd quarter. Vanguard Group Inc now owns 2,085,556 shares of the specialty pharmaceutical company’s stock valued at $8,030,000 after buying an additional 433,969 shares in the last quarter. Vanguard Group Inc. grew its holdings in AcelRx Pharmaceuticals by 26.3% in the 3rd quarter. Vanguard Group Inc. now owns 2,085,556 shares of the specialty pharmaceutical company’s stock valued at $8,030,000 after buying an additional 433,969 shares in the last quarter. Monashee Investment Management LLC grew its holdings in AcelRx Pharmaceuticals by 1,516.8% in the 4th quarter. Monashee Investment Management LLC now owns 1,652,190 shares of the specialty pharmaceutical company’s stock valued at $3,817,000 after buying an additional 1,550,000 shares in the last quarter. Finally, Two Sigma Investments LP grew its holdings in AcelRx Pharmaceuticals by 820.9% in the 4th quarter. Two Sigma Investments LP now owns 559,408 shares of the specialty pharmaceutical company’s stock valued at $1,292,000 after buying an additional 498,664 shares in the last quarter. Institutional investors and hedge funds own 18.69% of the company’s stock.

Shares of AcelRx Pharmaceuticals stock traded down $0.04 during trading on Friday, reaching $3.35. The company’s stock had a trading volume of 8,711 shares, compared to its average volume of 1,655,982. The company has a quick ratio of 6.73, a current ratio of 6.78 and a debt-to-equity ratio of 0.79. AcelRx Pharmaceuticals has a one year low of $1.99 and a one year high of $5.05. The stock has a market capitalization of $264.24 million, a price-to-earnings ratio of -4.12 and a beta of 2.15.

About AcelRx Pharmaceuticals

AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain.

See Also: Why are analyst ratings important in trading stocks?

Get a free copy of the Zacks research report on AcelRx Pharmaceuticals (ACRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.